Use of Propranolol Blockade to Explore the Pharmacology of GSK961081, a Bi-Functional Bronchodilator, in Healthy Volunteers: Results from Two Randomized Trials

Virginia Norris · Claire Ambery

Abstract

Purpose The objective of this study was to explore the pharmacology of GSK961081, a bi-functional bronchodilator, in healthy volunteers.

Methods Two randomized, double-blind, placebo-controlled studies were conducted. Following optimization of the propranolol dosing regimen (study 1), we conducted a five-period crossover study (study 2) in which subjects received the following treatments: dry powder inhaler (DPI) GSK961081 400 µg + oral placebo, DPI GSK961081 1,200 µg + oral placebo, DPI GSK961081 400 µg + oral propranolol 80 mg, DPI GSK961081 1,200 µg + oral propranolol 80 mg and DPI and oral placebo. GSK961081 (or inhaled placebo) was dosed at 0 h. Propranolol (or oral placebo) was dosed at -8, -2, 4, 10, and 16 h. The primary endpoint for both studies was bronchodilation, measured by specific airway conductance (sGaw), which was assessed at 0, 1, 4, 7, 12, 22, and 24 h in study 2. Tolerability and pharmacokinetics were secondary endpoints.

Results Studies 1 and 2 enrolled 18 and 23 subjects, respectively. In study 2, bronchodilation was seen for 24 h following GSK961081 400 and 1,200 µg. In the presence of β2 blockade, GSK961081 1,200 µg demonstrated bronchodilation in the first 4 h after dosing (treatment difference from placebo: 1.193; 90 % CI 1.117–1.274), but not at 4 h onwards. Adverse events were reported for 21 (study 1) and 15 subjects (study 2); none were serious, and there were no deaths.

Conclusion The duration of bronchodilation as a result of receiving the muscarinic antagonist component alone was shorter than that from the muscarinic antagonist β2 agonist combination. Removing the β2 agonist component may underestimate the contribution of the muscarinic antagonist component to the bronchodilation of the combination.

Key Points

GSK961081 is a novel bi-functional molecule that combines muscarinic antagonism (MA) and β2 agonism (BA) in a single molecule (MABA).

Bronchodilation following inhaled β2 agonist and anti-muscarinic agents can be measured by specific airway conductance (sGaw) in healthy volunteers. We used this endpoint, in the presence and absence of propranolol, to explore the pharmacology of GSK961081.

The duration of bronchodilation following GSK961081 from the muscarinic antagonist component alone was shorter than that from the MABA combination. However, removing the β2 component may underestimate the contribution of the muscarinic antagonist component to the bronchodilation of the combination.
1 Introduction

Inhaled bronchodilators are the mainstay of the symptomatic treatment of chronic obstructive pulmonary disease (COPD), and both long-acting β₂ agonists (LABAs) and long-acting muscarinic antagonists (LAMAs) are frequently prescribed as maintenance therapy. A combination of these agents can provide greater efficacy for patients who remain symptomatic on LABA or LAMA monotherapy, and a number of studies have demonstrated a superior bronchodilation effect with combined LABA and LAMA compared with the individual agents alone [1–6].

GSK961081 is a novel bi-functional molecule (or dual pharmacophore) that combines muscarinic antagonism (MA) and β₂ agonism (BA) in a single molecule (MABA). Pre-clinical data showed GSK961081 to be a potent functional antagonist of muscarinic receptors, as well as a potent, selective, and full agonist at the β₂ adrenoceptor, which produced significant and sustained bronchoprotection that was significantly greater than that with either of the MA or BA components alone [7, 8]. Clinically, GSK961081 at 400 and 1,200 µg once daily for 2 weeks demonstrated sustained bronchodilation similar to a combination of tiotropium 18 µg once daily plus salmeterol 50 µg twice daily but with a more rapid onset of action in patients with moderate COPD [9]. Additionally, a dose of 400 µg once a day for 28 days resulted in a forced expiratory volume in 1 s (FEV₁) of 215 (139–291 at 95% confidence interval) mL greater than placebo in patients with moderate and severe COPD [10]. It may be necessary to understand the relative contribution of the β₂ agonist versus anti-muscarinic components of such a molecule in humans. One way to do that is to block one of the components. Bronchodilation following inhaled β₂ agonist and anti-muscarinic agents can be measured by specific airway conductance (sGaw) in healthy volunteers [11–16]. Inhibition of β₂ agonist-mediated bronchodilation (as measured by sGaw) in healthy volunteers by the non-selective β-blocker propranolol has been reported previously [17–21]. However, published studies have generally looked at the effect of a single dose of propranolol on a β₂ agonist over a relatively short (a few hours) period of time, have been small, and have used various doses of propranolol and β₂ agonist with various degrees of inhibition of bronchodilation. Propranolol alone does not affect sGaw in healthy volunteers [19]. However, there were no published data on the effects of β blockade on sGaw following an inhaled anti-muscarinic alone or the combination of inhaled β₂ agonist and anti-muscarinic.

We therefore conducted and report two studies. Study 1 was conducted to confirm a dosing regimen of the β antagonist propranolol, which prevents the increase in sGaw to a β₂ agonist over 24 h and had acceptable tolerability. It was also to confirm that the β antagonist propranolol did not prevent an increase in sGaw in response to an anti-muscarinic and also to characterize the effect on sGaw of a combination of an anti-muscarinic and β₂ agonist and the effect of propranolol on the combination. Study 2 reports bronchodilation following the administration of GSK961081 in healthy volunteers in the presence and absence of propranolol.

2 Methods

2.1 Subjects

Healthy adult male or female (study 1 only, as reproductive toxicology had not been completed for GSK961081 at the time of study) subjects aged 18–50 years inclusive with a body mass index (BMI) within the range 19–29.9 kg/m² were included. Subjects were required to be non-smokers for at least 6 months before the study, have no history of respiratory disease, and have an FEV₁ ≥ 80% predicted and a FEV₁/forced expiratory vital capacity (FVC) ratio ≥ 0.7. Subjects were also required to have an increase in sGaw of ≥ 15% over pre-dose baseline within 2 h of administration of salbutamol 600 µg by metered dose inhaler (MDI) at screening or in the 3 months before screening and have an increase in sGaw of ≥ 25% over pre-dose baseline within 2 h following ipratropium bromide 40 µg at screening or in the 3 months before screening.

2.2 Study Design

Study 1 was a randomized, double-blind (with respect to propranolol administration), open (with respect to bronchodilator administration), six-period crossover design (GSK), London, UK, study number: MAB114954; www.clinicaltrials.gov: NCT00549120) conducted at Parexel Clinical Research Unit (CRU), UK, between 10 September 2007 and 22 October 2007. At study period 1, subjects received propranolol 80 mg (five doses at 6-h intervals) or placebo (five doses at 6-h intervals). At study periods 2, 3, and 4, subjects received each of the following three treatments in randomized order: propranolol 80 mg (five doses at 6-h intervals) + MDI salbutamol 600 µg (four doses at 6-h intervals); placebo (five doses at 6-h intervals) + MDI salbutamol 600 µg (four doses at 6-h intervals); or propranolol 80 mg (five doses at 6-h intervals) or placebo (five doses at 6-h intervals) (whichever treatment was not taken in session 1). At study periods 5 and 6, subjects received propranolol 80 mg (two doses at 6-h intervals) + MDI ipratropium 40 µg (two doses at 6-h intervals).
intervals) + MDI salbutamol 600 μg (one dose); and placebo (two doses at 6-h intervals) + MDI ipratropium 40 μg (two doses at 6-h intervals) + MDI salbutamol 600 μg (one dose). In study periods 1–4, propranolol was dosed at 0, 6, 12, 18, and 24 h and salbutamol was dosed at 2, 8, 14, and 20 h. In study periods 5 and 6, propranolol was dosed at 0 and 6 h, ipratropium at 2 and 8 h, and salbutamol at 8 h. Subjects were randomized to treatment sequences in accordance with the randomization schedule generated by Clinical Pharmacology Statistics and Programming (GlaxoSmithKline), using validated software (RandAll; GlaxoSmithKline). The placebo tablets (white in color) did not exactly match the propranolol tablets (pink in color), and the blind was maintained by blindfolding the subjects for propranolol or placebo administration.

Study 2 was a double-blind, placebo-controlled, five-period crossover design (GSK study number: MAB110553; www.clinicaltrials.gov: NCT00687700) conducted at Parexel CRU, UK, between 10 March 2008 and 27 May 2008. Subjects received each of the five treatments in randomized order: dry powder inhaler (DPI) GSK961081 400 μg + oral placebo, DPI GSK961081 1,200 μg + oral placebo, DPI GSK961081 400 μg + oral propranolol 80 mg, DPI GSK961081 1,200 μg + oral propranolol 80 mg, and inhaled DPI and oral placebo. GSK961081 (or inhaled placebo) was dosed at 0 h. Propranolol (or oral placebo) was dosed at −8, −2, 4, 10, and 16 h. Subjects were randomized to treatment sequences in accordance with the randomization schedule generated by Discovery Biometrics, prior to the start of the study, using validated software (RandAll). The placebo tablets (white in color) did not exactly match the propranolol tablets (pink in color), and tablets were over-encapsulated to maintain the blind.

Both studies included a washout of at least 7 days between treatments, and subjects attended a follow-up visit for safety approximately 1 week after completion of the study periods. The study protocols and informed consent were approved by the relevant ethics committees. Written informed consent was obtained from each subject before enrollment.

2.3 Pharmacodynamic Assessment (Primary Endpoint, Both Studies)

Three sGaw measurements, using whole body plethysmography, were performed at each of the following time points and the mean used in the data analysis. In study 1, sGaw was measured at 0, 3, 6, 9, 15, and 26 h during study periods 1–4 and at 0, 3, 6, and 9 h during study periods 5 and 6. In study 2, sGaw was measured at 0, 1, 4, 7, 12, 22, and 24 h.

2.4 Pharmacokinetic Assessment (Secondary Endpoint, Both Studies)

2.4.1 Propranolol

Blood (2 mL) for the determination of plasma propranolol concentrations were collected pre-dose, 3, 4, 6, 9, 15, 26, and 28 h post-dose in study 1, and −8, −2, 4, 10, 16, and 24 h post-GSK961081 dose in study 2. Plasma samples were analyzed for propranolol using a validated analytical method based on turbulent flow extraction, followed by TFC-LC-MS/MS analysis. The lower limit of quantification (LLQ) for propranolol was 1 ng/mL, using a 20-μL aliquot of human plasma with a higher limit of quantification (HLQ) of 250 ng/mL.

2.4.2 GSK961081 (Study 2 Only)

Blood samples (2 mL) for the determination of plasma concentrations of GSK961081 (study 2) were collected pre-GSK961081 dose and 0.5, 1, 2, and 4 h post-dose. Human plasma samples were analyzed for GSK961081 using a validated analytical method based on protein precipitation, followed by HPLC/MS/MS analysis. The LLQ for GSK961081 was 25 pg/mL using a 50-μL aliquot of human plasma with a HLQ of 25,000 pg/mL. The computer systems that were used on this study to acquire and quantify data included Analyst Version 1.4.1 and SMS2000 versions 1.6 and 2.0.

Quality control (QC) samples for both the propranolol and the GSK961081 assays were prepared at three different analyte concentrations and stored with study samples, and were analyzed with each batch of samples against separately prepared calibration standards. For the analyses to be acceptable, no more than one-third of the total QC results and no more than one-half of the results from each concentration level were to deviate from the nominal concentration by more than 15 %. The applicable analytical runs met all predefined run acceptance criteria.

2.4.3 Safety (Secondary Endpoint, Both Studies)

Safety laboratory tests were conducted at screening visit and follow-up for both studies and also 32 h after each inhaled dose for study 2. 12-lead electrocardiogram (ECG), blood pressure, and heart rate were collected frequently throughout both studies. Glucose and potassium were also collected frequently during study 2. Adverse events (AEs) were collected.

△ Adis
2.5 Dose Rationale

2.5.1 GSK961081

Doses of 400 and 1,200 µg were selected as these were studied in a 14-day efficacy study in patients with COPD; these doses gave comparable efficacy [9].

2.5.2 Salbutamol

A dose of salbutamol 600 µg 6 hourly (four doses) was selected to maintain β-agonist activity over the 24-h period. Whilst lower doses would give effective bronchodilation [12], it was important to test the effectiveness of the propranolol regimen at higher than effective bronchodilator doses.

2.5.3 Ipratropium

Ipratropium 40 µg was selected as this dose has been shown to have effective bronchodilation [13] in healthy volunteers. It was also important to use a dose that was at the lower end of the effective dose range.

2.5.4 Propranolol

For study 1, a dose of propranolol 80 mg 6 hourly (five doses in periods 1–4 and two doses in periods 5 and 6) was selected. Using published propranolol information on its pharmacokinetics in humans [22] and its in vitro affinity for the β2 receptor (pA2 = 9.4, competitive antagonist [23]), various propranolol dosing scenarios were simulated using Berkeley Madonna version 8.3.14 to determine a dosing regimen to maintain plasma propranolol concentrations above the in vitro predicted 90 % effective concentration (EC90). The final propranolol dosing regimen selection was based on clinical safety experience [24] and the simulated scenarios, and allowed for the dosing interval of propranolol to be increased from once every 6 h to once every 8 h if tolerability issues arose.

For study 2, a dose of 80 mg propranolol 6 hourly (five doses) was selected. The dose selection was based on the results of study 1, where plasma propranolol concentrations were above the in vitro predicted EC90 (~ 10.53 ng/mL) in all but 2 % of samples, indicating that adequate propranolol levels were achieved (Fig. 1). In addition, a population pharmacokinetic model was fitted to the study 1 propranolol data to evaluate how many propranolol doses to administer prior to GSK91081 and to determine whether four rather than five propranolol doses would be sufficient. It was determined by simulation that administering two propranolol doses prior to GSK961081 and three propranolol doses post GSK961081 would maintain the lower bound of the model predicted plasma propranolol concentration profile above the in vitro predicted EC90 over the duration under investigation (Fig. 1). This was also determined by simulation for a propranolol dose of 80 mg, thus enabling dose modification if tolerability issues arose.

2.6 Statistical Methods

2.6.1 Pharmacodynamics

In study 1, a total of 18 subjects were randomized, with the aim that 16 subjects would complete the study with evaluable data; 16 evaluable subjects was calculated to provide approximately 90 % power to detect the non-inferiority at 5 % significance level, assuming within- and between-subject standard deviations of 0.124 and 0.146 for sGaw, respectively. Serial sGaw data were analyzed using mixed effects modeling, following a natural logarithmic transformation. Non-inferiority tests were performed. The upper limit of 90 % confidence interval (CI) of the treatment ratio was compared with 1.15 to assess the non-inferiority of propranolol + salbutamol versus placebo. The lower limit of CI of the treatment ratio was compared with 0.87 to assess the non-inferiority of propranolol + ipratropium versus placebo + ipratropium and propranolol + salbutamol + ipratropium versus placebo + salbutamol + ipratropium.

For study 2, a total of 23 subjects were randomized, with the aim that 20 subjects would complete the study with evaluable data. No formal sample size calculation was conducted, as no formal hypothesis was to be tested; the focus was on estimation. The primary endpoint, serial sGaw, was analyzed, following a natural logarithmic transformation, using a mixed effects model. The model fitted treatment, time, period, and treatment by time as fixed effects; subject-level baseline, period-level baseline,
and period-level baseline by time as continuous covariates; and subject as a random effect. Comparisons were made between GSK961081 + propranolol and placebo treatment groups with the two different GSK961081 doses and at various time points. Point estimates and corresponding 90 % CIs were constructed for the estimated differences.

### 2.6.2 Pharmacokinetics

**Propranolol:** In study 1, plasma propranolol concentration–time data were analyzed by non-compartmental methods using WinNonlin 4.1 Software (Pharsight, Mountain View, CA, USA) to determine, for the first propranolol dosing interval, the area under the curve from time 0 to 6 h ($AUC_t$), peak concentration ($C_{\text{max}}$), and time to reach peak ($t_{\text{max}}$). In addition, for study 1, a one-compartment model with oral absorption was fitted to the propranolol concentration–time data for all dosing intervals using the software NONMEM VI.

**GSK961081:** In study 2, plasma GSK961081 concentration–time data were analyzed by non-compartmental methods using WinNonlin 4.1 Software to determine the AUC to last quantifiable concentration ($AUC_t$), $C_{\text{max}}$, $t_{\text{max}}$, and time of last quantifiable concentration ($t_{\text{last}}$).

### 3 Results

#### 3.1 Subject Disposition

Demographic and baseline characteristics are summarized in Table 1. Eight male and ten female healthy volunteers, mean age 29.6 years (range 21–46) and mean BMI 23.7 kg/m² (range 19.6–28.9) were randomized and completed study 1. Study 2 enrolled 23 healthy male volunteers, mean age 32.0 years (range 20–49) and mean BMI 24.7 kg/m² (range 20.3–29.9). A total of 21 subjects completed the study; two subjects were withdrawn due to protocol violations (one positive result for drugs of abuse, one positive for cotinine).

#### 3.2 Pharmacodynamic Results

In study 1, propranolol alone did not affect $sGaw$ (Fig. 2a; Table 2). Inhalation of salbutamol 600 µg resulted in an expected increase in $sGaw$ (Fig. 2a; Table 2). No significant bronchodilation was observed at the last time point after inhalation of salbutamol, probably because the final $sGaw$ measurement was taken too long after the last salbutamol dose. Propranolol prevented the increase in $sGaw$ in response to salbutamol 600 µg (Fig. 2a); $sGaw$ following propranolol + salbutamol was non-inferior to placebo (Table 2).

In study 1, propranolol did not prevent the $sGaw$ response to ipratropium 40 µg (Fig. 2b); $sGaw$ following propranolol + ipratropium was non-inferior to placebo + ipratropium (Table 2). Addition of salbutamol 600 µg to ipratropium 40 µg showed a small trend to increased $sGaw$ compared with when salbutamol 600 µg was added to ipratropium 40 µg in the presence of propranolol (Fig. 2b: 9-h time point), but the comparison showed that salbutamol + ipratropium + propranolol was non-inferior to salbutamol + ipratropium (Table 2).

In study 2, bronchodilation was seen for 24 h following a single dose of both 400 and 1,200 µg GSK961081 (Fig. 3). In the presence of effective $\beta_2$ blockade, GSK961081 1,200 µg demonstrated bronchodilation in the first 4 h after dosing (treatment difference from placebo at 1 h: 1.206 [90 % CI 1.126–1.292] and 4 h: 1.124 [90 % CI 1.078–1.173]) but not at 7 h onwards (Table 3). In the presence of effective $\beta_2$ blockade, GSK961081 400 µg demonstrated bronchodilation in the first 1 h after dosing (treatment difference from placebo: 1.193 [90 % CI 1.117–1.274]), but not at 4 h onwards (Table 3).

#### 3.3 Pharmacokinetic Results

##### 3.3.1 Propranolol

In study 1, plasma propranolol concentrations were above the in vitro predicted $EC_{90}$ ($\sim 10.53$ ng/mL) in all but 2 % of samples. There was no apparent difference in exposure to propranolol when administered alone or in combination with either salbutamol or ipratropium and salbutamol (Table 4). The propranolol population pharmacokinetic model gave a reasonable fit to the observed data (Fig. 1) and model predicted $AUC_t$, $C_{\text{max}}$, and $t_{\text{max}}$ were comparable to the non-compartmental analysis results (data not shown).

In study 2, plasma propranolol concentrations were above the in vitro predicted $EC_{90}$ ($\sim 10.53$ ng/mL) in all but 0.87 % of samples, all of which were prior to GSK961081 administration.

##### 3.3.2 GSK961081

In study 2, plasma GSK961081 systemic exposure ($C_{\text{max}}$ and $AUC_{(0-t)}$) was increased by approximately 60 % in the presence of propranolol (Table 5). In the absence of propranolol, systemic exposure to GSK961081 was in line with systemic exposure previously achieved in healthy volunteers at similar dose levels. Propranolol was not administered in the absence of GSK961081 in this study; however, comparable trough propranolol levels were achieved in study 1 after the first dose of propranolol 80 mg (data not shown).
3.4 Safety Results

In study 1, a total of 15 subjects experienced AEs. The most frequently reported AEs were headache (21 reports), tremor (15), and dizziness (13 reports). All AEs were rated as being mild or moderate in intensity, and no serious AEs were reported. One subject (salbutamol vs. placebo) missed one dose of propranolol due to an increase in corrected QT.

Table 1 Summary of baseline and demographic characteristics (studies 1 and 2)

| Characteristics | Study 1 (MAB104954) N = 18 | Study 2 (MAB110553) N = 23 |
|-----------------|------------------------------|-----------------------------|
| Age, years      | 29.6 (21–46)                 | 32.0 (20–49)                 |
| Male            | 8 (44)                       | 23 (100)                    |
| Ethnicity       |                              |                             |
| Hispanic/Latino | 1 (6)                        | 2 (9)                       |
| Not Hispanic/Latino | 17 (94)               | 21 (91)                     |
| Race            |                              |                             |
| African American/African heritage | 3 (17)           | 1 (4)                       |
| Asian–Central/South Asian heritage | 2 (11)          | 2 (9)                       |
| Asian–East Asian heritage | 0 (0)               | 1 (4)                       |
| Asian–Japanese heritage | 1 (6)             | 0 (0)                       |
| Asian–South East Asian heritage | 0 (0)          | 2 (9)                       |
| Native Hawaiian or other Pacific Islander | 1 (6)         | 0 (0)                       |
| White–White Caucasian/European heritage | 10 (56)       | 17 (74)                     |
| Mixed race      | 1 (6)                        | 0 (0)                       |
| Height, cm      | 172.7 (161–191)              | 173.3 (157–193)             |
| Weight, kg      | 70.8 (56.1–86.3)             | 74.23 (60–93)               |
| BMI, kg/m²      | 23.67 (19.6–28.9)            | 24.70 (20.3–29.6)           |

Data are presented as mean (range) or n (%) unless otherwise indicated.

BMI body-mass index

Table 2 Summary of statistical analysis of log-transformed specific airway resistance (1/KPa*s) data (study 1)

| Treatment                  | H | N  | Adjusted geometric mean | Treatment ratio |
|----------------------------|---|----|--------------------------|-----------------|
|                            |   |    | Estimate | SE logs | Estimate | 90 % CI |
| PRO + SAL (vs. PL)         | 3 | 18 | 0.824  | 0.0249 | 1.069    | 1.012–1.130 |
|                            | 6 | 18 | 0.778  | 0.0311 | 0.966    | 0.900–1.037 |
|                            | 9 | 18 | 0.841  | 0.0330 | 1.025    | 0.951–1.106 |
|                            | 15| 18 | 0.780  | 0.0355 | 1.043    | 0.961–1.131 |
|                            | 26| 18 | 0.762  | 0.0257 | 0.961    | 0.907–1.018 |
| PRO only (vs. PL)          | 3 | 18 | 0.965  | 0.0249 | 1.253    | 1.185–1.325 |
|                            | 6 | 18 | 0.932  | 0.0311 | 1.157    | 1.078–1.243 |
|                            | 9 | 18 | 1.045  | 0.0329 | 1.273    | 1.180–1.374 |
|                            | 15| 18 | 0.990  | 0.0354 | 1.322    | 1.218–1.435 |
|                            | 26| 18 | 0.808  | 0.0261 | 1.020    | 0.962–1.082 |
| PRO + IPR (vs. PL + IPR)   | 3 | 18 | 0.753  | 0.0270 | 0.978    | 0.925–1.034 |
|                            | 6 | 18 | 0.772  | 0.0330 | 0.959    | 0.893–1.030 |
|                            | 9 | 18 | 0.808  | 0.0347 | 0.984    | 0.912–1.062 |
|                            | 15| 18 | 0.748  | 0.0371 | 0.999    | 0.920–1.085 |
|                            | 26| 18 | 0.767  | 0.0278 | 0.968    | 0.913–1.027 |
| PRO + IPR + SAL (vs. PL + IPR + SAL) | 3 | 18 | 0.901  | 0.0278 | 0.973    | 0.934–1.014 |
|                            | 9 | 18 | 0.905  | 0.0316 | 0.926    | 0.876–0.978 |

CI confidence interval, H hour, IPR ipratropium, PL placebo, PRO propranolol, SAL salbutamol, SE standard error

3.4 Safety Results

In study 1, a total of 15 subjects experienced AEs. The most frequently reported AEs were headache (21 reports), tremor (15), and dizziness (13 reports). All AEs were rated as being mild or moderate in intensity, and no serious AEs were reported. One subject (salbutamol + placebo) missed one dose of propranolol due to an increase in corrected QT.

△ Adis
interval (QTc) of potential clinical concern to the investigator. There were no clinically important findings in other safety assessments.

In study 2, a total of 21 subjects experienced AEs. The most frequently reported AEs were dysgeusia (24 reports), dizziness (seven reports), and headache (six reports). All AEs were rated as being mild or moderate in intensity, and no serious AEs were reported. One subject (GSK961081 1,200 μg + propranolol) had a PR interval of 224 at 6 h after the first dose of propranolol and therefore did not have further doses of propranolol. The efficacy data for this subject were not included in the analysis for this treatment. There were no clinically important findings in other safety assessments. Potassium and glucose data were similar at all time points (pre-dose, 1, 4, and 24 h) across all treatments, including placebo.

Fig. 2  a sGaw following placebo alone, propranolol alone, salbutamol alone, and propranolol + salbutamol (study 1). b sGaw following propranolol + ipratropium and propranolol + ipratropium + salbutamol (study 1). sGaw specific airway conductance
Discussion

In study 1, inhalation of salbutamol 600 \( \mu \text{g} \) (+ placebo) resulted in the expected bronchodilation. At the final time point for sGaw assessment, 6 h after the last dose of salbutamol, there was no increase in sGaw. This is because the final sGaw measurement was taken too long after the last salbutamol dose. Our data are consistent with published data showing that sGaw 6 h after salbutamol is the same as after placebo [14]. The propranolol regimen used prevented the increase in sGaw in response to salbutamol 600 \( \mu \text{g} \), but did not prevent the sGaw response to ipratropium 40 \( \mu \text{g} \). Therefore, we have demonstrated a propranolol dosing regimen that was effective in preventing bronchodilation to a supra-therapeutic dose of \( \beta_2 \) agonist, but that did not prevent the bronchodilation to a low dose of anti-muscarinic.

This is the first study where the effect of combined salbutamol and ipratropium on sGaw has been explored in healthy volunteers. Whilst there was a trend to an increase in sGaw when salbutamol was added to ipratropium, this assessment does not appear to be sensitive enough to detect the benefit of the two mechanisms in healthy volunteers. This is in contrast to this endpoint in COPD patients, where a single dose of salmeterol 50 \( \mu \text{g} \) (+ fluticasone propionate 500 \( \mu \text{g} \) + tiotropium 18 \( \mu \text{g} \) was significantly more effective than tiotropium or salmeterol (+ fluticasone) alone in improving post-dose sGaw [25].

Fig. 3 Estimated treatment ratios (and 90 % CIs) sGaw versus placebo (study 2). CI confidence interval, sGaw specific airway conductance

4 Discussion

In study 1, inhalation of salbutamol 600 \( \mu \text{g} \) (+ placebo) resulted in the expected bronchodilation. At the final time point for sGaw assessment, 6 h after the last dose of salbutamol, there was no increase in sGaw. This is because the final sGaw measurement was taken too long after the last salbutamol dose. Our data are consistent with published data showing that sGaw 6 h after salbutamol is the same as after placebo [14]. The propranolol regimen used prevented the increase in sGaw in response to salbutamol 600 \( \mu \text{g} \), but did not prevent the sGaw response to ipratropium 40 \( \mu \text{g} \). Therefore, we have demonstrated a propranolol dosing regimen that was effective in preventing bronchodilation to a supra-therapeutic dose of \( \beta_2 \) agonist, but that did not prevent the bronchodilation to a low dose of anti-muscarinic.

This is the first study where the effect of combined salbutamol and ipratropium on sGaw has been explored in healthy volunteers. Whilst there was a trend to an increase in sGaw when salbutamol was added to ipratropium, this assessment does not appear to be sensitive enough to detect the benefit of the two mechanisms in healthy volunteers. This is in contrast to this endpoint in COPD patients, where a single dose of salmeterol 50 \( \mu \text{g} \) (+ fluticasone propionate 500 \( \mu \text{g} \) + tiotropium 18 \( \mu \text{g} \) was significantly more effective than tiotropium or salmeterol (+ fluticasone) alone in improving post-dose sGaw [25].

Table 3 Summary of statistical analysis of log-transformed specific airway resistance (1/KPa*s) data (study 2)

| Treatment          | H  | N  | Adjusted geometric mean | Treatment ratio (vs. Placebo) |
|--------------------|----|----|-------------------------|-------------------------------|
|                    |    |    | Estimate | SE logs | Estimate | 90 % CI   |
| 081 400 \( \mu \text{g} \) + PRO | 1  | 23 | 1.176    | 0.0291  | 1.193    | 1.117–1.274 |
|                    | 4  | 23 | 1.050    | 0.0195  | 1.025    | 0.985–1.067 |
|                    | 7  | 23 | 1.044    | 0.0269  | 1.014    | 0.955–1.077 |
|                    | 12 | 23 | 0.983    | 0.0223  | 1.010    | 0.963–1.059 |
|                    | 22 | 23 | 0.923    | 0.0226  | 0.951    | 0.906–0.998 |
|                    | 24 | 22 | 0.985    | 0.0239  | 0.998    | 0.948–1.051 |
| 081 1,200 \( \mu \text{g} \) + PRO | 1  | 22 | 1.189    | 0.0309  | 1.206    | 1.126–1.292 |
|                    | 4  | 22 | 1.151    | 0.0207  | 1.124    | 1.078–1.173 |
|                    | 7  | 22 | 1.049    | 0.0286  | 1.019    | 0.956–1.085 |
|                    | 12 | 22 | 0.989    | 0.0236  | 1.016    | 0.966–1.068 |
|                    | 22 | 22 | 0.927    | 0.0240  | 0.955    | 0.907–1.005 |
|                    | 24 | 22 | 0.976    | 0.0249  | 0.989    | 0.938–1.044 |
| 081 400 \( \mu \text{g} \) only | 1  | 23 | 1.154    | 0.0292  | 1.171    | 1.099–1.248 |
|                    | 4  | 23 | 1.145    | 0.0196  | 1.118    | 1.075–1.162 |
|                    | 7  | 23 | 1.110    | 0.0270  | 1.078    | 1.017–1.143 |
|                    | 12 | 23 | 1.093    | 0.0224  | 1.123    | 1.072–1.176 |
|                    | 22 | 23 | 1.050    | 0.227   | 1.081    | 1.031–1.133 |
|                    | 24 | 23 | 1.092    | 0.0235  | 1.107    | 1.053–1.163 |
| 081 1,200 \( \mu \text{g} \) only | 1  | 23 | 1.177    | 0.0292  | 1.194    | 1.120–1.273 |
|                    | 4  | 23 | 1.190    | 0.0196  | 1.161    | 1.117–1.207 |
|                    | 7  | 23 | 1.136    | 0.0270  | 1.104    | 1.041–1.170 |
|                    | 12 | 23 | 1.112    | 0.0224  | 1.142    | 1.091–1.196 |
|                    | 22 | 23 | 1.079    | 0.0227  | 1.111    | 1.060–1.165 |
|                    | 24 | 23 | 1.110    | 0.0236  | 1.125    | 1.071–1.182 |

CI confidence interval, \( H \) hour, PRO propranolol, SE standard error, 081 GSK961081

\( \Delta \) Adis
Table 4  Plasma propranolol pharmacokinetic parameters (study 1)

| Treatment          | N/n | \( C_{\text{max}} \) (ng/mL) | \( \text{AUC}_{0-t} \) (ng.h/mL) | \( t_{\text{max}} \) (h) |
|--------------------|-----|-------------------------------|-------------------------------|------------------|
| PRO only           | 18/18 | 55.12 (38.84–78.21) | 201.5 (142.2–285.6) | 3.05 (3.00–4.00) |
| PRO + SAL          | 18/18 | 63.97 (45.96–89.04) | 234.0 (166.3–329.2) | 3.05 (3.02–5.90) |
| PRO + IPR + SAL    | 18/18 | 69.78 (52.04–93.55) | 258.6 (191.7–348.8) | 3.07 (3.00–4.00) |

\( \text{AUC} \) area under the concentration time curve from time 0 to 6 h, \( CI \) confidence interval, \( C_{\text{max}} \) maximum observed plasma concentration, \( IPR \) ipratropium, \( PRO \) propranolol, \( SAL \) salbutamol, \( t_{\text{max}} \) time to maximum observed concentration

\( a \) Geometric mean (95% CI)

\( b \) Median (range)

Table 5  Plasma GSK961081 pharmacokinetic parameters (study 2)

| Treatment          | N/n | \( C_{\text{max}} \) (pg/mL) | \( \text{AUC}_{0-t} \) (pg.h/mL) | \( t_{\text{max}} \) (h) | \( t_{\text{last}} \) (h) |
|--------------------|-----|-------------------------------|-------------------------------|------------------|------------------|
| 081 400 µg + PRO   | 23/23 | 165,236 (147,292–185,367) | 204,816 (178,161–235,459) | 0.50 (0.43–1.12) | 2.02 (0.98–3.88) |
| 081 1,200 µg + PRO  | 23/23 | 528,172 (464,459–600,624) | 870,949 (768,076–987,602) | 0.98 (0.47–1.08) | 3.83 (2.02–3.88) |
| 081 400 µg only    | 23/23 | 101,052 (89,546–114,036) | 121,249 (97,867–150,218) | 0.95 (0.45–1.12) | 2.02 (0.97–3.98) |
| 081 1,200 µg only  | 23/23 | 307,291 (264,677–356,765) | 585,333 (502,799–681,416) | 0.98 (0.48–1.07) | 3.85 (2.02–3.90) |

\( \text{AUC} \) area under the concentration–time curve, \( CI \) confidence interval, \( C_{\text{max}} \) maximum observed plasma concentration, \( PRO \) propranolol, \( t_{\text{max}} \) time to maximum observed concentration, 081 GSK961081

\( a \) Geometric mean (95% CI)

\( b \) Median (range)

In study 2, bronchodilation was seen for 24 h following a single dose of both 400 and 1,200 µg GSK961081. In the presence of effective \( \beta_2 \) blockade, GSK961081 1,200 µg demonstrated bronchodilation in the first 4 h after dosing but not at 7 h onwards, whilst GSK961081 400 µg demonstrated bronchodilation in the first 1 h after dosing, but not at 4 h onwards. Therefore, in this model, the MA alone bronchodilation is of shorter duration than the bronchodilation achieved with the MA/BA activity combined.

This assessment may underestimate the MA contribution to the MA/BA activity combined. Amplification of bronchodilation achieved by one component by the other component is believed to contribute to the benefit of combined anti-muscarinic and \( \beta_2 \) agonist [26]. Investigative studies have suggested that the enhanced MABA activity compared with the single ligands may be due to crosstalk between the engaged M3 and \( \beta_2 \) receptors [27]. Crosstalk between the receptors could be reduced or abolished by blocking the \( \beta \) receptor as has been done in the reported clinical studies.

Therefore, removing the BA component completely may underestimate the contribution of the MA component to the bronchodilation of the combination by removing the potential for amplification of one mechanism by the other. In addition, the response in healthy volunteers may not be the same as in COPD patients. In COPD patients, salbutamol and ipratropium have been added at 1, 12, and 24 h following single doses of GSK961081 400 and 1,200 µg [28]. In that study, the additional bronchodilation following salbutamol and ipratropium inhalation was similar, and this indirect assessment may indicate that the activities of the MA and BA components are of a similar magnitude. A further limitation is that the study looked at single-dose GSK961081 only; investigating the response after repeat dosing would also be of interest.

In both studies, all dosing regimens were well tolerated. There were no serious AEs, and all AEs reported were consistent with the known effects of propranolol and salbutamol or the AEs previously reported with GSK961081 [9, 10, 28].

Pharmacokinetic modeling was used to inform propranolol dose selection for the two studies. The propranolol dosing regimen (five doses of propranolol 80 mg at 6-h intervals) was safe and well tolerated and shown to provide plasma propranolol concentrations above the in vitro predicted EC90 throughout the treatment session. This propranolol dosing regimen was effective at preventing the increase in sGaw in response to salbutamol 600 µg. However, it is possible that propranolol did not completely block the effects of the BA component of the MABA, and some of the bronchodilation seen following MABA in the presence of propranolol is due to residual BA effect. There was no apparent difference in exposure to propranolol when administered alone or in combination with either salbutamol or ipratropium and salbutamol. GSK961081 systemic exposure (\( C_{\text{max}} \) and \( \text{AUC} \)) was increased by approximately 60% in the presence of propranolol. In vitro data suggest that the difference is unlikely to be a result of...
metabolic interaction or plasma protein-binding displacement. Propranolol is a cytochrome P450 (CYP)1A2, CYP2D6, and CYP2C19 substrate with a minor route (~15%) via direct glucuronidation; whereas that of GSK961081 appears to be by direct glucuronidation and a CYP3A4 substrate. A postulated reason for the difference is that GSK961081 apparent clearance is decreased as a result of a decrease in liver blood flow in the presence of propranolol (β2 adrenoceptor mediated).

In conclusion, in this healthy volunteer model, the duration of bronchodilation from the MA component alone was of shorter duration than that achieved from the MA/BA combination.

Acknowledgments The authors thank Maurice Leonard for clinical and operational support, and Chang-Qing Zhu and Nigel Dallow for statistical input. The authors thank the investigators, staff and subjects at Parexel CRU, the clinical site for both studies.

Funding disclosure Both of the studies described in this manuscript were funded by GSK. GlaxoSmithKline study numbers: study 1 MAB104954 [NCT00549120]; study 2 MAB110553 [NCT00687700]).

Ethics statement The study protocols (GSK study numbers MAB104954 and MAB110553; NCT00687700 and NCT00549120) and informed consent were approved by the relevant ethics committees. Written informed consent was obtained from each subject before enrolment.

Contributions and Conflict of interest Authors’ statement V Norris and C Ambery contributed to study design, oversaw the study conduct, contributed to and approved the final statistical analysis plan, and interpreted the data. V Norris lead the development of the manuscript and C Ambery reviewed and contributed to all drafts; both authors approved the final version. V Norris and C Ambery are employed by, and hold stocks and shares in, GSK.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References
1. Van Noord JA, Aumann JL, Janssens E, et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J. 2005;26:214–22.
2. Van Noord JA, Aumann JL, Janssens E, et al. Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms. Respir Med. 2010;104:995–1004.
3. Van Noord JA, Aumann JL, Janssens E, et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest. 2006;129:509–17.
4. Terrazzo C, Petroiani A, Conti V, et al. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med. 2008;102:1701–7.
5. Van Noord JA, Buhl R, LaForce C, et al. QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease. Thorax. 2010;65:1086–91.
6. Cazzola M, Segreti A, Matera M. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201–8.
7. Aiyar J, Steinfeld T, Pulido-Rios MT, et al. Characterization of TD-5959: a novel bifunctional molecule with muscarinic antagonist and beta2-adrenergic agonist activity. Am J Respir Crit Care Med. 2009;179:A4552 (abstract).
8. Pulido-Rios MT, McNamara A, Kwan K, et al. TD-5959: a novel bifunctional muscarinic antagonist—β2-adrenergic agonist with potent and sustained in vivo bronchodilator activity in guinea pigs. Am J Respir Crit Care Med. 2009;179:A6195 (abstract).
9. Bateman E, Kornmann O, Ambery C, et al. Pharmacodynamics of GSK961081, a bi-functional molecule, in patients with COPD. Pulm Pharmacol Ther. 2013;26:581–7.
10. Wielders PL, Ludwig-Sengpiel A, Locantore N, et al. A new class of bronchodilator improves lung function in COPD: a trial with GSK961081. Eur Respir J. 2013;42:972–81.
11. Bengendal A, Johansson A, Bake B, et al. Airway effects of salmeterol in healthy individuals. Pulm Pharmacol. 1995;8:283–8.
12. Houghton C, Woodcock A, Singh D. A comparison of lung function methods for assessing dose-response effects of salbutamol. Br J Clin Pharmacol. 2004;58:134–41.
13. Singh D, Tal-Singer R, Falberman I, et al. Plethysmography and impulse oscillometry assessment of tiotropium and ipratropium bromide: a randomised double blind, placebo controlled, crossover study in healthy subjects. Br J Clin Pharmacol. 2006;61:398–404.
14. Pullerits T, Ventresca P, Lotvall J. The duration of bronchodilation of salmeterol and salbutamol as measured by specific airway conductance in healthy subjects. Pulm Pharmacol Ther. 2011;24:55–8.
15. Schellhous V, Ferrer P, Janss J, et al. Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase 1 study. Br J Clin Pharmacol. 2010;69:458–64.
16. Spring J, C lague J, Ind P. A comparison of the effect of salmeterol and salbutamol in normal subjects. Br J Clin Pharmacol. 1992;33:139–41.
17. Bauer K, Rakusan S, Kaig K. Pulmonary effects of long term beta 2 blockade in healthy subjects: comparative study of metoprolol OROS. Am Heart J. 1990;120:473–7.
18. Gribbin H, Baldwin C, Tatterfield AE. Quantitative assessment of bronchial beta adrenoceptor blockade in man. Br J Clin Pharmacol. 1979;7:551–6.
19. Palminteri R, Kaig K. Time course of the bronchial response to salbutamol after placebo, beta2x and propranolol. Eur J Clin Pharmacol. 1983;24:741–5.
20. Lipworth BJ, Brown RA, McDevitt DG. Assessment of airways, tremor and chronotropic responses to inhaled salbutamol in the quantification of beta 2-adrenoceptor blockade. Br J Clin Pharmacol. 1989;28:95–102.
21. Warren J, Monaghan A. Effect of penbutolol and propranolol on normal airway response to salbutamol. Clin Pharmacol Ther. 1984;36:47–50.
22. Wojcicki J, Sulzyce-Bielicka V, Kutrzeba J, et al. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. J Clin Pharmacol. 1999;39:826–33.
23. Naline E, Sarria B, Ertzbischoff O, et al. Comparative beta adrenoceptor blocking effects of propranolol, bisoprolol, atenolol, acebutolol and diaetolol on the human isolated bronchus. Br J Clin Pharmacol. 1990;30:135–9.
24. Evans GH, Shand DG. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973;14:487–93.
25. Singh D, Brook J, Hagan G, et al. Superiority of triple therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592–8.

26. Cazzola M, Molimard M. The scientific rationale for combining long-acting β2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257–67.

27. Aiyar J, Calixto J, Linnevers C, et al. Crosstalk between heterologously expressed M3-muscarinic receptors and β2 adrenoceptors. Am J Respir Crit Care Med. 2009;179:A1920 (abstract).

28. Norris V, Ambery C. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther. 2013;26:574–80.